Association of recombinant human growth hormone replacement with improved arterial oxygenation in patients with hepatopulmonary syndrome secondary to hypopituitarism: a retrospective case series
Objective This retrospective single-arm case series described the changes in arterial oxygenation in patients with hepatopulmonary syndrome (HPS) secondary to hypopituitarism who received recombinant human growth hormone (rhGH) replacement. Methods A total of 21 patients were enrolled, with etiologies including pituitary stalk interruption syndrome (n = 3), post-resection craniopharyngioma (n = 11), and sellar germ cell tumors (n = 7). The median interval from hypopituitarism diagnosis to HPS onset was 9 years. Ten patients received rhGH therapy. The 11 non-GH patients served as a baseline descriptive comparison; follow-up oxygenation data were available for only 3, precluding longitudinal between-group comparison. Results Among the ten treated patients, rhGH therapy was associated with average improvement in PO 2 (from 48.6 ± 4.2 mmHg to 91.0 ± 6.0 mmHg; P = 0.0006) and average reductions in P(A–a)O 2 (from 60.8 ± 4.8 mmHg to 12.2 ± 5.5 mmHg; P < 0.0001). Eight of ten treated patients maintained normal PO 2 levels during extended therapy lasting 8 to 84 months, while two showed partial improvement without reaching the normal threshold (41→57 mmHg and 46→61 mmHg). In three patients with available data, liver stiffness measurement decreased significantly after 7 to 13 months of rhGH treatment (from 33.0 ± 7.6 kPa to 24.7 ± 6.4 kPa). Given the small number of patients (n = 3), these data are presented descriptively only. Conclusion rhGH replacement was associated with significantly improved oxygenation and sustained therapeutic benefits in patients with hypopituitarism-associated HPS, supporting further investigation of its potential as an adjunctive therapy; however, randomized controlled studies are needed.
Authors
- Min Nie (ORCID: https://orcid.org/0000-0001-7179-0044)
- 马海陆
- Jiangfeng Mao (ORCID: https://orcid.org/0000-0003-0157-1545)
- Qin Han (ORCID: https://orcid.org/0000-0002-7317-0823)
- Xueyan Wu
- Hongying Liu
- Xi Wang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fendo.2026.1977951
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00